Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)

INTRODUCTION: Triple antiemetic therapy with neurokinin-1 receptor antagonist, 5-hydroxytryptamine type 3 receptor antagonist, and dexamethasone has been widely recommended for high emetogenic chemotherapeutic (HEC) agents and regimens, including anthracycline combined with cyclophosphamide (AC). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozeki, Rie, Iihara, Hirotoshi, Shimokawa, Mototsugu, Hashimoto, Hironobu, Abe, Masakazu, Mukohara, Toru, Bando, Hiroko, Hayashi, Toshinobu, Kawazoe, Hitoshi, Komoda, Masayo, Yanai Takahashi, Takako, Saito, Mitsue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896054/
https://www.ncbi.nlm.nih.gov/pubmed/35236735
http://dx.doi.org/10.1136/bmjopen-2021-058755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896054/
https://www.ncbi.nlm.nih.gov/pubmed/35236735
http://dx.doi.org/10.1136/bmjopen-2021-058755

Ejemplares similares